Proactive Investors - Run By Investors For Investors

Over 75% of patients now enrolled into ANGLE’s Parsortix clinical study

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019
blood cells
ANGLE’s technology allows scientists to harvest tumour cells in the bloodstream and analyse them

ANGLE PLC (LON:AGL) continues to make “good progress” with the enrolment for the clinical study of its Parsortix cancer detection technology.

So far, over 75% of the required 400 patients – 200 with cancer and 200 healthy – have been enrolled in the study.

READ: Scientists make major breakthrough with Parsortix

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019.

Away from the trial, ANGLE has been carrying out more work of its own on Parsortix, which has yielded “new insights” into the system.

Multi-billion-dollar market

“Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well,” said chief executive Andrew Newland.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.”

He added: “This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Shares fell 4.4% to 41.1p.

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use